TX-MAVENIR
17.3.2022 14:03:02 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announces its complete Software as a Service (SaaS) based Business Communications portfolio, including customer engagement, business messaging, Communications Platform as a Service (CPaaS), Unified Communications as a Service (UCaaS) and Contact Center as a Service (CCaaS).
Mavenir leverages its global expertise in mobile networks, its relationships with hundreds of CSPs, enterprises and partners, and its leadership in the mobile messaging space to provide a Business Communications portfolio that enables omni-channel customer experiences to businesses of all sizes. The MAVbiz portfolio includes the following solutions:
> |
Mavenir Engage — Customer Engagement as a Service solution that combines multi-channel business messaging connectors (SMS, RCS, Apple Messages for Business, Google Business Messages) with business automations, chatbots, visual flow builder and campaign manager capabilities to enable conversational commerce capabilities for businesses of all sizes. |
||||
> |
Mavenir CPaaS — A full set of programmable APIs and turnkey applications (Smart 2FA, Number Masking, Call Routing) that allow businesses and developers to integrate communication capabilities into business processes and applications. |
||||
> |
Mavenir Connect — Unified Communication as a Service (UCaaS) solution that delivers a powerful set of high-definition voice, video, messaging, and meetings capabilities to allow workers to collaborate with colleagues and connect with customers anywhere, anytime and on any device. |
||||
> |
Mavenir Care — Contact Center as a Service (CCaaS) solution with omni-channel integrations, flexible and open APIs, business processes integrations (CRMs, AI platforms), visual IVR builder, and robust analytics and reporting. |
“Gartner predicts that 80% of customer service organizations will abandon mobile apps in favor of messaging by 2025i ," said Jorgen Nilsson, President, Enterprise Connect Business, Mavenir. “As a leader in messaging, with 60% SMS market shareii and over 3 billion mobile messaging subscribers globally, Mavenir is unlocking the power of business messaging to create a superior customer experience, leveraging our messaging footprint, certification as an Apple Messages for Business MSP and other key ecosystem partnerships.”
Mavenir’s Business Communications Solutions are designed to fit the needs of businesses of all sizes, micro, small and medium businesses to large enterprises, and are brought to market through CSPs, Channels or SIs, which can apply their own brand to the solutions and leverage Mavenir’s professional services, white-label marketing collateral, business operations and partner ecosystem relationships for fast time-to-market and subscriber growth.
Mavenir’s solutions deliver omni-channel interactions in every aspect of business communications and enable businesses with an affordable and fast enablement of their digital presence. By combining these solutions businesses can:
> |
Use Mavenir Engage chatbots and automations to offload repetitive tasks but leverage the human-in-the-loop (HITL) API to transfer messaging conversations to a representative using a Mavenir Care agent console |
||||
> |
Use Mavenir CPaaS APIs to send calls or text conversations from a business website or application to an employee using a Mavenir Connect endpoint. |
||||
> |
Transfer a customer call from the Mavenir Care agent console to another employee using a Mavenir Connect endpoint. |
||||
> |
Deflect incoming calls from the Mavenir Care contact center to a Mavenir Engage chatbot during busy hours or when the business is closed. |
Market dynamics are pointing towards omni-channel messaging in all aspects of business communication. 79% of consumers prefer live chats because they offer instant responsesiii and 53% of businesses saw an increase in workload due to the pandemiciv . Messaging increases productivity by allowing employees to handle multiple communications simultaneously.
Mavenir will be showcasing its Business Communications portfolio at Enterprise Connect 2022. Booth #1500 from March 21 to 24 in Orlando, Florida.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
| ______________________________ |
i Source: Gartner Newsroom |
ii Source: Mavenir based on GSMA Operator Subscribers |
iii Source: 99 Firms – Live Chat Statistics |
iv Source: User Testing – 2021 CX Industry Report |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005116/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom